Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15554361,absorption rate constants (alpha),The intranasal absorption of hPTH (1-34) was rapid; the absorption rate constants (alpha) were 33.2+/-24 h(-1) [without bovine serum albumin (BSA)] and 9.8+/-5.1 h(-1) (with 1% BSA).,"Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15554361/),1/[h],33.2,16931,DB06285,Teriparatide
,15554361,absorption rate constants (alpha),The intranasal absorption of hPTH (1-34) was rapid; the absorption rate constants (alpha) were 33.2+/-24 h(-1) [without bovine serum albumin (BSA)] and 9.8+/-5.1 h(-1) (with 1% BSA).,"Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15554361/),1/[h],9.8,16932,DB06285,Teriparatide
,15554361,maximum plasma concentrations (Cmax),The maximum plasma concentrations (Cmax): 151+/-24 pg/mL (without BSA) and 176+/-37 (with 1% BSA) were attained within approximately 15 min.,"Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15554361/),[pg] / [ml],151,16933,DB06285,Teriparatide
,15554361,maximum plasma concentrations (Cmax),The maximum plasma concentrations (Cmax): 151+/-24 pg/mL (without BSA) and 176+/-37 (with 1% BSA) were attained within approximately 15 min.,"Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15554361/),,176,16934,DB06285,Teriparatide
,15554361,bioavailabilities (Fabs),The intranasal bioavailabilities (Fabs) were 12.1+/-3.4% (without BSA) and 17.6+/-1.5% (with 1% BSA).,"Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15554361/),%,12.1,16935,DB06285,Teriparatide
,15554361,bioavailabilities (Fabs),The intranasal bioavailabilities (Fabs) were 12.1+/-3.4% (without BSA) and 17.6+/-1.5% (with 1% BSA).,"Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15554361/),%,17.6,16936,DB06285,Teriparatide
,3967464,mean transit times,"Bioassayable PTH-like activity then disappeared from the plasma (mean transit times 5.8 and 8.6 min), approximately twice as fast as immuno-reactivity.",Pharmacokinetics of synthetic human parathyroid hormone 1-34 in man measured by cytochemical bioassay and radioimmunoassay. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3967464/),min,5.8,56445,DB06285,Teriparatide
,3967464,mean transit times,"Bioassayable PTH-like activity then disappeared from the plasma (mean transit times 5.8 and 8.6 min), approximately twice as fast as immuno-reactivity.",Pharmacokinetics of synthetic human parathyroid hormone 1-34 in man measured by cytochemical bioassay and radioimmunoassay. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3967464/),min,8.6,56446,DB06285,Teriparatide
,22289659,Cmax,"Mean+/-SD hPTH134 Cmax values were, respectively, 74+/-59, 138+/-101, 717+/-496, and 1624+/-1579 pg/mL for 1, 2.5, 5, and 10 mg doses of this peptide administered with 200 mg 5-CNAC; while mean+/-SD AUC (0-last) values were, respectively, 30+/-40, 62+/-69, 320+/-269, and 627+/-633 h*pg/mL.",The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),[pg] / [ml],74,84959,DB06285,Teriparatide
,22289659,Cmax,"Mean+/-SD hPTH134 Cmax values were, respectively, 74+/-59, 138+/-101, 717+/-496, and 1624+/-1579 pg/mL for 1, 2.5, 5, and 10 mg doses of this peptide administered with 200 mg 5-CNAC; while mean+/-SD AUC (0-last) values were, respectively, 30+/-40, 62+/-69, 320+/-269, and 627+/-633 h*pg/mL.",The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),[pg] / [ml],138,84960,DB06285,Teriparatide
,22289659,Cmax,"Mean+/-SD hPTH134 Cmax values were, respectively, 74+/-59, 138+/-101, 717+/-496, and 1624+/-1579 pg/mL for 1, 2.5, 5, and 10 mg doses of this peptide administered with 200 mg 5-CNAC; while mean+/-SD AUC (0-last) values were, respectively, 30+/-40, 62+/-69, 320+/-269, and 627+/-633 h*pg/mL.",The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),[pg] / [ml],717,84961,DB06285,Teriparatide
,22289659,Cmax,"Mean+/-SD hPTH134 Cmax values were, respectively, 74+/-59, 138+/-101, 717+/-496, and 1624+/-1579 pg/mL for 1, 2.5, 5, and 10 mg doses of this peptide administered with 200 mg 5-CNAC; while mean+/-SD AUC (0-last) values were, respectively, 30+/-40, 62+/-69, 320+/-269, and 627+/-633 h*pg/mL.",The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),[pg] / [ml],1624,84962,DB06285,Teriparatide
,22289659,AUC (0-last),"Mean+/-SD hPTH134 Cmax values were, respectively, 74+/-59, 138+/-101, 717+/-496, and 1624+/-1579 pg/mL for 1, 2.5, 5, and 10 mg doses of this peptide administered with 200 mg 5-CNAC; while mean+/-SD AUC (0-last) values were, respectively, 30+/-40, 62+/-69, 320+/-269, and 627+/-633 h*pg/mL.",The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),[h·pg] / [ml],30,84963,DB06285,Teriparatide
,22289659,AUC (0-last),"Mean+/-SD hPTH134 Cmax values were, respectively, 74+/-59, 138+/-101, 717+/-496, and 1624+/-1579 pg/mL for 1, 2.5, 5, and 10 mg doses of this peptide administered with 200 mg 5-CNAC; while mean+/-SD AUC (0-last) values were, respectively, 30+/-40, 62+/-69, 320+/-269, and 627+/-633 h*pg/mL.",The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),[h·pg] / [ml],62,84964,DB06285,Teriparatide
,22289659,AUC (0-last),"Mean+/-SD hPTH134 Cmax values were, respectively, 74+/-59, 138+/-101, 717+/-496, and 1624+/-1579 pg/mL for 1, 2.5, 5, and 10 mg doses of this peptide administered with 200 mg 5-CNAC; while mean+/-SD AUC (0-last) values were, respectively, 30+/-40, 62+/-69, 320+/-269, and 627+/-633 h*pg/mL.",The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),[h·pg] / [ml],320,84965,DB06285,Teriparatide
,22289659,AUC (0-last),"Mean+/-SD hPTH134 Cmax values were, respectively, 74+/-59, 138+/-101, 717+/-496, and 1624+/-1579 pg/mL for 1, 2.5, 5, and 10 mg doses of this peptide administered with 200 mg 5-CNAC; while mean+/-SD AUC (0-last) values were, respectively, 30+/-40, 62+/-69, 320+/-269, and 627+/-633 h*pg/mL.",The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),[h·pg] / [ml],627,84966,DB06285,Teriparatide
,22289659,Cmax,The corresponding estimates for teriparatide 20 μg sc were 149+/-35 for Cmax and 236+/-58 for AUC (0-last) Ionized calcium remained within normal limits in all treatment groups except for 3 isolated events.,The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),,149,84967,DB06285,Teriparatide
,22289659,Cmax,The corresponding estimates for teriparatide 20 μg sc were 149+/-35 for Cmax and 236+/-58 for AUC (0-last) Ionized calcium remained within normal limits in all treatment groups except for 3 isolated events.,The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),,35,84968,DB06285,Teriparatide
,22289659,AUC (0-last),The corresponding estimates for teriparatide 20 μg sc were 149+/-35 for Cmax and 236+/-58 for AUC (0-last) Ionized calcium remained within normal limits in all treatment groups except for 3 isolated events.,The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),,236,84969,DB06285,Teriparatide
,21888960,drug loading efficiency,"The microemulsion showed high drug loading efficiency (83%) and permeability, and significantly higher resistance to proteolysis in vitro study.",Preliminary evaluation of a novel oral delivery system for rhPTH1-34: in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21888960/),%,83,89494,DB06285,Teriparatide
,21888960,relative oral bioavailability,The relative oral bioavailability was 5.4% and 12.0% when delivered to gastric and ileum.,Preliminary evaluation of a novel oral delivery system for rhPTH1-34: in vitro and in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21888960/),%,5.4,89495,DB06285,Teriparatide
,21888960,relative oral bioavailability,The relative oral bioavailability was 5.4% and 12.0% when delivered to gastric and ileum.,Preliminary evaluation of a novel oral delivery system for rhPTH1-34: in vitro and in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21888960/),%,12.0,89496,DB06285,Teriparatide
,8263137,t1/2,"Clearance of the peptide from the circulation followed an expontential pattern, with a mean t1/2 of 75 min.",Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263137/),min,75,101757,DB06285,Teriparatide
,31181662,bioavailability,"Previously, we have published an encouraging bioavailability (78%), relative to subcutaneous injection in a small animal preclinical model, for a liquid nasal spray formulation containing the permeation enhancer polyethylene glycol (15)-hydroxystearate (Solutol® HS15).",Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181662/),%,78,117407,DB06285,Teriparatide
,31181662,50% clearance time,"The 50% clearance time was 17.8 min (minimum 10.9, maximum 74.3 min).",Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181662/),min,17.8,117408,DB06285,Teriparatide
,31181662,50% clearance time,"The 50% clearance time was 17.8 min (minimum 10.9, maximum 74.3 min).",Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181662/),min,74.3,117409,DB06285,Teriparatide
,31181662,plasma Cmax,"For PTH 1-34, mean plasma Cmax of 5 pg/mL and 253 pg/mL were obtained for the nasal spray and subcutaneous injection respectively; relative bioavailability of the nasal spray was ≤1%.",Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181662/),[pg] / [ml],5,117410,DB06285,Teriparatide
,31181662,plasma Cmax,"For PTH 1-34, mean plasma Cmax of 5 pg/mL and 253 pg/mL were obtained for the nasal spray and subcutaneous injection respectively; relative bioavailability of the nasal spray was ≤1%.",Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181662/),[pg] / [ml],253,117411,DB06285,Teriparatide
≤,31181662,relative bioavailability,"For PTH 1-34, mean plasma Cmax of 5 pg/mL and 253 pg/mL were obtained for the nasal spray and subcutaneous injection respectively; relative bioavailability of the nasal spray was ≤1%.",Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181662/),%,1,117412,DB06285,Teriparatide
,31181662,relative bioavailability,"In this preclinical model, the relative bioavailability of liquid and powder nasal formulations was 1.4% and 1.0% respectively.",Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181662/),%,1.4,117413,DB06285,Teriparatide
,31181662,relative bioavailability,"In this preclinical model, the relative bioavailability of liquid and powder nasal formulations was 1.4% and 1.0% respectively.",Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181662/),%,1.0,117414,DB06285,Teriparatide
,31181662,absolute bioavailability,"The absolute bioavailability of subcutaneously administered PTH 1-34 (mean 77%, range 55-108%) in sheep was in agreement with published human data for teriparatide (up to 95%).",Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181662/),%,77,117415,DB06285,Teriparatide
up to,31181662,absolute bioavailability,"The absolute bioavailability of subcutaneously administered PTH 1-34 (mean 77%, range 55-108%) in sheep was in agreement with published human data for teriparatide (up to 95%).",Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181662/),%,95,117416,DB06285,Teriparatide
,23719683,maximum (peak) plasma drug concentration (C max),"The mean maximum (peak) plasma drug concentration (C max) values for patients receiving tablets at week 0 (n = 32) and week 24 (n = 28) were 295 and 207 pg/mL, respectively.",Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH₂] in postmenopausal women with osteoporosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719683/),[pg] / [ml],295,118716,DB06285,Teriparatide
,23719683,maximum (peak) plasma drug concentration (C max),"The mean maximum (peak) plasma drug concentration (C max) values for patients receiving tablets at week 0 (n = 32) and week 24 (n = 28) were 295 and 207 pg/mL, respectively.",Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH₂] in postmenopausal women with osteoporosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719683/),[pg] / [ml],207,118717,DB06285,Teriparatide
,23719683,time to reach maximum (peak) plasma concentration following drug administration (t max),The mean time to reach maximum (peak) plasma concentration following drug administration (t max) for both week 0 and week 24 was 3.25 h.,Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH₂] in postmenopausal women with osteoporosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719683/),h,3.25,118718,DB06285,Teriparatide
,23719683,area under the concentration-time curve (AUC),"The mean area under the concentration-time curve (AUC) for week 0 and week 24 was 178 and 141 pg·h/mL, respectively.",Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH₂] in postmenopausal women with osteoporosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719683/),[h·pg] / [ml],178,118719,DB06285,Teriparatide
,23719683,area under the concentration-time curve (AUC),"The mean area under the concentration-time curve (AUC) for week 0 and week 24 was 178 and 141 pg·h/mL, respectively.",Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH₂] in postmenopausal women with osteoporosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719683/),[h·pg] / [ml],141,118720,DB06285,Teriparatide
,18065105,peak plasma concentration (Cmax),"The mean peak plasma concentration (Cmax) were 123.6, 195.6, and 318.2 pg x mL(-1) respectively, and were reached from 25.6 to 36.1 min after subcutaneous administration.",Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065105/),[pg] / [ml],123.6,121607,DB06285,Teriparatide
,18065105,peak plasma concentration (Cmax),"The mean peak plasma concentration (Cmax) were 123.6, 195.6, and 318.2 pg x mL(-1) respectively, and were reached from 25.6 to 36.1 min after subcutaneous administration.",Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065105/),[pg] / [ml],195.6,121608,DB06285,Teriparatide
,18065105,peak plasma concentration (Cmax),"The mean peak plasma concentration (Cmax) were 123.6, 195.6, and 318.2 pg x mL(-1) respectively, and were reached from 25.6 to 36.1 min after subcutaneous administration.",Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065105/),[pg] / [ml],318.2,121609,DB06285,Teriparatide
,18065105,elimination halflife (t(1/2)),"After Cmax was reached, the plasma drug level decreased quickly, with elimination halflife (t(1/2)) of 53.9 to 64.1 min.",Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065105/),min,53.9 to 64.1,121610,DB06285,Teriparatide
,18065105,AUC(0-infinity),"The mean AUC(0-infinity) (the area under the plasma concentration versus time curve from time zero to infinite) of rhPTH (1-34) were 11794.2 +/- 974.8, 21606.7 +/- 4753.9, 33877.0 +/- 8374.4 pg x min x mL(-1), respectively.",Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065105/),[min·pg] / [ml],11794.2,121611,DB06285,Teriparatide
,18065105,AUC(0-infinity),"The mean AUC(0-infinity) (the area under the plasma concentration versus time curve from time zero to infinite) of rhPTH (1-34) were 11794.2 +/- 974.8, 21606.7 +/- 4753.9, 33877.0 +/- 8374.4 pg x min x mL(-1), respectively.",Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065105/),[min·pg] / [ml],21606.7,121612,DB06285,Teriparatide
,18065105,area under the plasma concentration versus time curve from time zero to infinite,"The mean AUC(0-infinity) (the area under the plasma concentration versus time curve from time zero to infinite) of rhPTH (1-34) were 11794.2 +/- 974.8, 21606.7 +/- 4753.9, 33877.0 +/- 8374.4 pg x min x mL(-1), respectively.",Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065105/),[min·pg] / [ml],21606.7,121613,DB06285,Teriparatide
,18065105,area under the plasma concentration versus time curve from time zero to infinite,"The mean AUC(0-infinity) (the area under the plasma concentration versus time curve from time zero to infinite) of rhPTH (1-34) were 11794.2 +/- 974.8, 21606.7 +/- 4753.9, 33877.0 +/- 8374.4 pg x min x mL(-1), respectively.",Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065105/),[min·pg] / [ml],33877.0,121614,DB06285,Teriparatide
,18065105,AUC(0-t),"The mean AUC(0-t) (the area under the plasma concentration versus time curve from time zero to the last quantifiable concentration) of rhPTH (1-34) were 9034.4 +/- 1073.9, 17883.3 +/- 4597.1, 31693.5 +/- 6574.8 pg x min x mL(-1), respectively.",Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065105/),[min·pg] / [ml],9034.4,121615,DB06285,Teriparatide
,18065105,AUC(0-t),"The mean AUC(0-t) (the area under the plasma concentration versus time curve from time zero to the last quantifiable concentration) of rhPTH (1-34) were 9034.4 +/- 1073.9, 17883.3 +/- 4597.1, 31693.5 +/- 6574.8 pg x min x mL(-1), respectively.",Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065105/),[min·pg] / [ml],17883.3,121616,DB06285,Teriparatide
,18065105,AUC(0-t),"The mean AUC(0-t) (the area under the plasma concentration versus time curve from time zero to the last quantifiable concentration) of rhPTH (1-34) were 9034.4 +/- 1073.9, 17883.3 +/- 4597.1, 31693.5 +/- 6574.8 pg x min x mL(-1), respectively.",Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065105/),[min·pg] / [ml],31693.5,121617,DB06285,Teriparatide
,18065105,area under the plasma concentration versus time curve from time zero to the last quantifiable concentration,"The mean AUC(0-t) (the area under the plasma concentration versus time curve from time zero to the last quantifiable concentration) of rhPTH (1-34) were 9034.4 +/- 1073.9, 17883.3 +/- 4597.1, 31693.5 +/- 6574.8 pg x min x mL(-1), respectively.",Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065105/),[min·pg] / [ml],9034.4,121618,DB06285,Teriparatide
,18065105,area under the plasma concentration versus time curve from time zero to the last quantifiable concentration,"The mean AUC(0-t) (the area under the plasma concentration versus time curve from time zero to the last quantifiable concentration) of rhPTH (1-34) were 9034.4 +/- 1073.9, 17883.3 +/- 4597.1, 31693.5 +/- 6574.8 pg x min x mL(-1), respectively.",Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065105/),[min·pg] / [ml],17883.3,121619,DB06285,Teriparatide
,18065105,area under the plasma concentration versus time curve from time zero to the last quantifiable concentration,"The mean AUC(0-t) (the area under the plasma concentration versus time curve from time zero to the last quantifiable concentration) of rhPTH (1-34) were 9034.4 +/- 1073.9, 17883.3 +/- 4597.1, 31693.5 +/- 6574.8 pg x min x mL(-1), respectively.",Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065105/),[min·pg] / [ml],31693.5,121620,DB06285,Teriparatide
,12916003,T max,"After pulmonary administration of Technosphere/PTH(1 - 34), PTH(1 - 34) appeared in the serum with a faster concentration increase (T max: pulmonary 10 +/- 5 min vs. subcutaneous 28 +/- 8 min, p < 0.001) and with higher maximal concentrations (C max : pulmonary 309 +/- 215 pmol/l vs. subcutaneous 102 +/- 45 pmol/l, p < 0.05) as compared to the subcutaneous injection.",Pilot study with technosphere/PTH(1-34)--a new approach for effective pulmonary delivery of parathyroid hormone (1-34). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12916003/),min,10,132876,DB06285,Teriparatide
,12916003,T max,"After pulmonary administration of Technosphere/PTH(1 - 34), PTH(1 - 34) appeared in the serum with a faster concentration increase (T max: pulmonary 10 +/- 5 min vs. subcutaneous 28 +/- 8 min, p < 0.001) and with higher maximal concentrations (C max : pulmonary 309 +/- 215 pmol/l vs. subcutaneous 102 +/- 45 pmol/l, p < 0.05) as compared to the subcutaneous injection.",Pilot study with technosphere/PTH(1-34)--a new approach for effective pulmonary delivery of parathyroid hormone (1-34). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12916003/),min,28,132877,DB06285,Teriparatide
,12916003,maximal concentrations (C max,"After pulmonary administration of Technosphere/PTH(1 - 34), PTH(1 - 34) appeared in the serum with a faster concentration increase (T max: pulmonary 10 +/- 5 min vs. subcutaneous 28 +/- 8 min, p < 0.001) and with higher maximal concentrations (C max : pulmonary 309 +/- 215 pmol/l vs. subcutaneous 102 +/- 45 pmol/l, p < 0.05) as compared to the subcutaneous injection.",Pilot study with technosphere/PTH(1-34)--a new approach for effective pulmonary delivery of parathyroid hormone (1-34). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12916003/),[pM] / [l],309,132878,DB06285,Teriparatide
,12916003,maximal concentrations (C max,"After pulmonary administration of Technosphere/PTH(1 - 34), PTH(1 - 34) appeared in the serum with a faster concentration increase (T max: pulmonary 10 +/- 5 min vs. subcutaneous 28 +/- 8 min, p < 0.001) and with higher maximal concentrations (C max : pulmonary 309 +/- 215 pmol/l vs. subcutaneous 102 +/- 45 pmol/l, p < 0.05) as compared to the subcutaneous injection.",Pilot study with technosphere/PTH(1-34)--a new approach for effective pulmonary delivery of parathyroid hormone (1-34). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12916003/),[pM] / [l],102,132879,DB06285,Teriparatide
,12916003,relative bioavailability,The relative bioavailability of pulmonary Technosphere/PTH(1 - 34) was calculated to be 48 %.,Pilot study with technosphere/PTH(1-34)--a new approach for effective pulmonary delivery of parathyroid hormone (1-34). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12916003/),%,48,132880,DB06285,Teriparatide
,31175387,Effective concentration (EC50),"Effective concentration (EC50) of PTX in RCO was 8.2 nM and plasma PTX level was 7 nM/mL after single oral dosing of 25 mg/kg, which was 1/6th the clinically used dose.",Reversal of Osteopenia in Ovariectomized Rats by Pentoxifylline: Evidence of Osteogenic and Osteo-Angiogenic Roles of the Drug. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31175387/),nM,8.2,134987,DB06285,Teriparatide
,20953593,half-life,"The pharmacokinetics of teriparatide were characterized by rapid absorption (maximum concentration achieved within 30 min) and rapid elimination (half-life of 1 h), resulting in a total duration of exposure to the peptide of approximately 4 h.",Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20953593/),h,1,148812,DB06285,Teriparatide
,24361089,t1/2,"The elimination half-life (t1/2) and the mean residence time extrapolated to infinity were significantly prolonged in the group with severe renal impairment (t1/2: 5.0 hours) compared with normal to mild and moderate impairment groups (t1/2: 1.5 hours and 1.2 hours, respectively).",Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: a pilot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24361089/),h,5.0,168306,DB06285,Teriparatide
,24361089,t1/2,"The elimination half-life (t1/2) and the mean residence time extrapolated to infinity were significantly prolonged in the group with severe renal impairment (t1/2: 5.0 hours) compared with normal to mild and moderate impairment groups (t1/2: 1.5 hours and 1.2 hours, respectively).",Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: a pilot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24361089/),h,1.5,168307,DB06285,Teriparatide
,24361089,t1/2,"The elimination half-life (t1/2) and the mean residence time extrapolated to infinity were significantly prolonged in the group with severe renal impairment (t1/2: 5.0 hours) compared with normal to mild and moderate impairment groups (t1/2: 1.5 hours and 1.2 hours, respectively).",Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: a pilot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24361089/),h,1.2,168308,DB06285,Teriparatide
,7829640,apparent t1/2,"Measurements of plasma immunoreactive peptide indicated a comparable volume of distribution for each, but the apparent t1/2 (8.3 +/- 1.6 min) and plasma clearance (4.0 +/- 1.4 L/min) for hPTHrP were significantly (P < 0.05) accelerated compared to those of hPTH (t1/2, 10.2 +/- 0.5 min; clearance, 2.0 +/- 0.4 L/min).",Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7829640/),min,8.3,188863,DB06285,Teriparatide
,7829640,plasma clearance,"Measurements of plasma immunoreactive peptide indicated a comparable volume of distribution for each, but the apparent t1/2 (8.3 +/- 1.6 min) and plasma clearance (4.0 +/- 1.4 L/min) for hPTHrP were significantly (P < 0.05) accelerated compared to those of hPTH (t1/2, 10.2 +/- 0.5 min; clearance, 2.0 +/- 0.4 L/min).",Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7829640/),[l] / [min],4.0,188864,DB06285,Teriparatide
,7829640,t1/2,"Measurements of plasma immunoreactive peptide indicated a comparable volume of distribution for each, but the apparent t1/2 (8.3 +/- 1.6 min) and plasma clearance (4.0 +/- 1.4 L/min) for hPTHrP were significantly (P < 0.05) accelerated compared to those of hPTH (t1/2, 10.2 +/- 0.5 min; clearance, 2.0 +/- 0.4 L/min).",Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7829640/),min,10.2,188865,DB06285,Teriparatide
,7829640,clearance,"Measurements of plasma immunoreactive peptide indicated a comparable volume of distribution for each, but the apparent t1/2 (8.3 +/- 1.6 min) and plasma clearance (4.0 +/- 1.4 L/min) for hPTHrP were significantly (P < 0.05) accelerated compared to those of hPTH (t1/2, 10.2 +/- 0.5 min; clearance, 2.0 +/- 0.4 L/min).",Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7829640/),[l] / [min],2.0,188866,DB06285,Teriparatide
,7829640,Peak plasma cAMP levels,"Peak plasma cAMP levels were 9-fold lower in response to hPTHrP (29.5 +/- 19 vs. 190 +/- 63 pmol/L; P < 0.01), and increases in urinary cAMP excretion were 5-fold lower (2.1 +/- 1.1 vs. 11.2 +/- 3.7 nmol/mmol creatinine; P < 0.01).",Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7829640/),[pM] / [l],29.5,188867,DB06285,Teriparatide
,7829640,Peak plasma cAMP levels,"Peak plasma cAMP levels were 9-fold lower in response to hPTHrP (29.5 +/- 19 vs. 190 +/- 63 pmol/L; P < 0.01), and increases in urinary cAMP excretion were 5-fold lower (2.1 +/- 1.1 vs. 11.2 +/- 3.7 nmol/mmol creatinine; P < 0.01).",Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7829640/),[pM] / [l],190,188868,DB06285,Teriparatide
,7829640,excretion,"Peak plasma cAMP levels were 9-fold lower in response to hPTHrP (29.5 +/- 19 vs. 190 +/- 63 pmol/L; P < 0.01), and increases in urinary cAMP excretion were 5-fold lower (2.1 +/- 1.1 vs. 11.2 +/- 3.7 nmol/mmol creatinine; P < 0.01).",Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7829640/),,2.1,188869,DB06285,Teriparatide
,7829640,excretion,"Peak plasma cAMP levels were 9-fold lower in response to hPTHrP (29.5 +/- 19 vs. 190 +/- 63 pmol/L; P < 0.01), and increases in urinary cAMP excretion were 5-fold lower (2.1 +/- 1.1 vs. 11.2 +/- 3.7 nmol/mmol creatinine; P < 0.01).",Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7829640/),,11.2,188870,DB06285,Teriparatide
,9773956,area under the plasma concentration-time curve (AUC),"The pharmacokinetic parameters of the intranasal PTH(1-34) (n = 4) thus estimated were as follows: the area under the plasma concentration-time curve (AUC) = 20,500+/-15,900(SD) pg.min/ml; the mean residence time (MRT) = 194+/-16.3(SD) min; and the maximal concentration (Cmax) = 98+/-51 (SD) pg/ml with the maximal time (Tmax) = 35.0+/-12.2(SD) min.",Development of a highly sensitive and specific two-site enzyme immunoassay for parathyroid hormone (1-34): application to pharmacokinetic study on intranasal parathyroid hormone (1-34) in human. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9773956/),[min·pg] / [ml],"20,500",193313,DB06285,Teriparatide
,9773956,mean residence time (MRT),"The pharmacokinetic parameters of the intranasal PTH(1-34) (n = 4) thus estimated were as follows: the area under the plasma concentration-time curve (AUC) = 20,500+/-15,900(SD) pg.min/ml; the mean residence time (MRT) = 194+/-16.3(SD) min; and the maximal concentration (Cmax) = 98+/-51 (SD) pg/ml with the maximal time (Tmax) = 35.0+/-12.2(SD) min.",Development of a highly sensitive and specific two-site enzyme immunoassay for parathyroid hormone (1-34): application to pharmacokinetic study on intranasal parathyroid hormone (1-34) in human. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9773956/),min,194,193314,DB06285,Teriparatide
,9773956,maximal concentration (Cmax),"The pharmacokinetic parameters of the intranasal PTH(1-34) (n = 4) thus estimated were as follows: the area under the plasma concentration-time curve (AUC) = 20,500+/-15,900(SD) pg.min/ml; the mean residence time (MRT) = 194+/-16.3(SD) min; and the maximal concentration (Cmax) = 98+/-51 (SD) pg/ml with the maximal time (Tmax) = 35.0+/-12.2(SD) min.",Development of a highly sensitive and specific two-site enzyme immunoassay for parathyroid hormone (1-34): application to pharmacokinetic study on intranasal parathyroid hormone (1-34) in human. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9773956/),[pg] / [ml],98,193315,DB06285,Teriparatide
,9773956,maximal time (Tmax),"The pharmacokinetic parameters of the intranasal PTH(1-34) (n = 4) thus estimated were as follows: the area under the plasma concentration-time curve (AUC) = 20,500+/-15,900(SD) pg.min/ml; the mean residence time (MRT) = 194+/-16.3(SD) min; and the maximal concentration (Cmax) = 98+/-51 (SD) pg/ml with the maximal time (Tmax) = 35.0+/-12.2(SD) min.",Development of a highly sensitive and specific two-site enzyme immunoassay for parathyroid hormone (1-34): application to pharmacokinetic study on intranasal parathyroid hormone (1-34) in human. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9773956/),min,35.0,193316,DB06285,Teriparatide
,27777391,tmax,"Pharmakokinetic(PK)study after a single Teriparatide injection of the daily dose in healthy Japanese postmenopausal women(n=18)revealed very rapid achievement of peak blood level(median of tmax=0.25 hr)followed by fast disappearance from the blood(mean t1/2=0.708 hr, n=17).","[Relationship of pharmacokinetics, changes of bone turnover markers and BMD/fractures efficacy during treatment with anabolic agents;Teriparatide daily and once weekly subcutaneous injections.] ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27777391/),h,0.25,226406,DB06285,Teriparatide
,27777391,t1/2,"Pharmakokinetic(PK)study after a single Teriparatide injection of the daily dose in healthy Japanese postmenopausal women(n=18)revealed very rapid achievement of peak blood level(median of tmax=0.25 hr)followed by fast disappearance from the blood(mean t1/2=0.708 hr, n=17).","[Relationship of pharmacokinetics, changes of bone turnover markers and BMD/fractures efficacy during treatment with anabolic agents;Teriparatide daily and once weekly subcutaneous injections.] ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27777391/),h,0.708,226407,DB06285,Teriparatide
,27777391,tmax,"PK study after injection of the higher weekly dose in healthy Japanese postmenopausal women(n=10)revealed a relatively slow achievement of the peak blood level(mean tmax=0.875 hr)compared to daily injections, followed by relatively slow disappearance from the blood(mean t1/2=1.295 hr).","[Relationship of pharmacokinetics, changes of bone turnover markers and BMD/fractures efficacy during treatment with anabolic agents;Teriparatide daily and once weekly subcutaneous injections.] ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27777391/),h,0.875,226408,DB06285,Teriparatide
,27777391,t1/2,"PK study after injection of the higher weekly dose in healthy Japanese postmenopausal women(n=10)revealed a relatively slow achievement of the peak blood level(mean tmax=0.875 hr)compared to daily injections, followed by relatively slow disappearance from the blood(mean t1/2=1.295 hr).","[Relationship of pharmacokinetics, changes of bone turnover markers and BMD/fractures efficacy during treatment with anabolic agents;Teriparatide daily and once weekly subcutaneous injections.] ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27777391/),h,1.295,226409,DB06285,Teriparatide
,24793535,Tmax,"After single and multiple subcutaneous administration of rhPTH(1-34), the drug was rapidly absorbed, with a Tmax of 20 to 30 minutes, and rapidly cleared from the plasma, with a t½ of 47.2 to 60.6 minutes.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human parathyroid hormone (1-34) in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24793535/),min,20 to 30,235171,DB06285,Teriparatide
,24793535,t½,"After single and multiple subcutaneous administration of rhPTH(1-34), the drug was rapidly absorbed, with a Tmax of 20 to 30 minutes, and rapidly cleared from the plasma, with a t½ of 47.2 to 60.6 minutes.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human parathyroid hormone (1-34) in healthy Chinese subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24793535/),min,47.2 to 60.6,235172,DB06285,Teriparatide
,27007999,Cmax,"Geometric mean (90% CI) Cmax for test and reference formulations were 165.86 (153.35 - 212.13) and 175.37 (164.04 - 221.04) pg/mL, the AUC0-t was 14,932 (5,275 - 15,752) and 14,153 (1,861 - 16,875) pg×min/mL, and the AUC0-∞ was 16,147 (15,047 - 18,799) and 15,467 (14,473 - 18,126) pg×min/mL, respectively.",Relative bioavailability between two teriparatide formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27007999/),[pg] / [ml],165.86,261917,DB06285,Teriparatide
,27007999,Cmax,"Geometric mean (90% CI) Cmax for test and reference formulations were 165.86 (153.35 - 212.13) and 175.37 (164.04 - 221.04) pg/mL, the AUC0-t was 14,932 (5,275 - 15,752) and 14,153 (1,861 - 16,875) pg×min/mL, and the AUC0-∞ was 16,147 (15,047 - 18,799) and 15,467 (14,473 - 18,126) pg×min/mL, respectively.",Relative bioavailability between two teriparatide formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27007999/),[pg] / [ml],175.37,261918,DB06285,Teriparatide
,27007999,AUC0-t,"Geometric mean (90% CI) Cmax for test and reference formulations were 165.86 (153.35 - 212.13) and 175.37 (164.04 - 221.04) pg/mL, the AUC0-t was 14,932 (5,275 - 15,752) and 14,153 (1,861 - 16,875) pg×min/mL, and the AUC0-∞ was 16,147 (15,047 - 18,799) and 15,467 (14,473 - 18,126) pg×min/mL, respectively.",Relative bioavailability between two teriparatide formulations in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27007999/),[min·pg] / [ml],"14,932",261919,DB06285,Teriparatide
,27007999,AUC0-t,"Geometric mean (90% CI) Cmax for test and reference formulations were 165.86 (153.35 - 212.13) and 175.37 (164.04 - 221.04) pg/mL, the AUC0-t was 14,932 (5,275 - 15,752) and 14,153 (1,861 - 16,875) pg×min/mL, and the AUC0-∞ was 16,147 (15,047 - 18,799) and 15,467 (14,473 - 18,126) pg×min/mL, respectively.",Relative bioavailability between two teriparatide formulations in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27007999/),[min·pg] / [ml],"14,153",261920,DB06285,Teriparatide
,27007999,AUC0-∞,"Geometric mean (90% CI) Cmax for test and reference formulations were 165.86 (153.35 - 212.13) and 175.37 (164.04 - 221.04) pg/mL, the AUC0-t was 14,932 (5,275 - 15,752) and 14,153 (1,861 - 16,875) pg×min/mL, and the AUC0-∞ was 16,147 (15,047 - 18,799) and 15,467 (14,473 - 18,126) pg×min/mL, respectively.",Relative bioavailability between two teriparatide formulations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27007999/),[min·pg] / [ml],"16,147",261921,DB06285,Teriparatide
,27007999,AUC0-∞,"Geometric mean (90% CI) Cmax for test and reference formulations were 165.86 (153.35 - 212.13) and 175.37 (164.04 - 221.04) pg/mL, the AUC0-t was 14,932 (5,275 - 15,752) and 14,153 (1,861 - 16,875) pg×min/mL, and the AUC0-∞ was 16,147 (15,047 - 18,799) and 15,467 (14,473 - 18,126) pg×min/mL, respectively.",Relative bioavailability between two teriparatide formulations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27007999/),[min·pg] / [ml],"15,467",261922,DB06285,Teriparatide
